NO981745L - Monoklonalt antistoff BR110 og anvendelse av dette - Google Patents
Monoklonalt antistoff BR110 og anvendelse av detteInfo
- Publication number
- NO981745L NO981745L NO981745A NO981745A NO981745L NO 981745 L NO981745 L NO 981745L NO 981745 A NO981745 A NO 981745A NO 981745 A NO981745 A NO 981745A NO 981745 L NO981745 L NO 981745L
- Authority
- NO
- Norway
- Prior art keywords
- antigen
- monoclonal antibody
- complex
- ligands
- ligand
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US564195P | 1995-10-19 | 1995-10-19 | |
| PCT/US1996/016070 WO1997014796A1 (en) | 1995-10-19 | 1996-10-07 | Monoclonal antibody br110 and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO981745D0 NO981745D0 (no) | 1998-04-17 |
| NO981745L true NO981745L (no) | 1998-04-17 |
| NO321548B1 NO321548B1 (no) | 2006-05-29 |
Family
ID=21716930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19981745A NO321548B1 (no) | 1995-10-19 | 1998-04-17 | Monoklonalt antistoff som binder seg til GA733-1-antigen, hybridom, konjugat, humant/muse-rekombinant antistoff, nukleinsyremolekyl, plasmid, vertsvektorsystem samt fremgangsmate for fremstilling av et protein. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US5840854A (no) |
| EP (1) | EP0856054B1 (no) |
| JP (1) | JP2001501801A (no) |
| AT (1) | ATE265532T1 (no) |
| AU (1) | AU7394296A (no) |
| CA (1) | CA2235269C (no) |
| DE (1) | DE69632333T2 (no) |
| ES (1) | ES2219699T3 (no) |
| IL (1) | IL123294A0 (no) |
| NO (1) | NO321548B1 (no) |
| WO (1) | WO1997014796A1 (no) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7354587B1 (en) * | 1994-07-06 | 2008-04-08 | Immunomedics, Inc. | Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines |
| US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
| US6366762B1 (en) * | 1999-03-31 | 2002-04-02 | Qualcomm, Inc. | System and method for measuring round trip delay on the paging and access channels |
| US6617432B1 (en) * | 1999-10-15 | 2003-09-09 | University Of Pittsburgh | Nuclear matrix proteins polynucleotide sequences encoding them and their use |
| US20030009781A1 (en) * | 2001-03-29 | 2003-01-09 | Allen Keith D. | Transgenic mice containing Kir3.3 potassium channel gene disruptions |
| US20020155109A1 (en) * | 2001-04-20 | 2002-10-24 | Lynch David H. | Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2 |
| US8435529B2 (en) | 2002-06-14 | 2013-05-07 | Immunomedics, Inc. | Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy |
| US9770517B2 (en) * | 2002-03-01 | 2017-09-26 | Immunomedics, Inc. | Anti-Trop-2 antibody-drug conjugates and uses thereof |
| US9745380B2 (en) | 2002-03-01 | 2017-08-29 | Immunomedics, Inc. | RS7 antibodies |
| CN101264325B (zh) | 2002-03-01 | 2017-03-01 | 免疫医疗公司 | Rs7抗体 |
| US9701754B1 (en) | 2002-10-23 | 2017-07-11 | City Of Hope | Covalent disulfide-linked diabodies and uses thereof |
| US7420041B2 (en) * | 2006-02-24 | 2008-09-02 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| US20080305104A1 (en) * | 2006-02-24 | 2008-12-11 | Young David S F | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| US20080131428A1 (en) * | 2006-02-24 | 2008-06-05 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| US20080213267A1 (en) * | 2006-02-24 | 2008-09-04 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| US8940871B2 (en) | 2006-03-20 | 2015-01-27 | The Regents Of The University Of California | Engineered anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting |
| JP4689521B2 (ja) * | 2006-04-07 | 2011-05-25 | 財団法人電力中央研究所 | 抗鉛モノクローナル抗体 |
| EP2197491A4 (en) | 2007-09-04 | 2011-01-12 | Univ California | HIGHAFFINE ANTI-PROSTATE STEM CELL ANTIGEN (PSCA) ANTIBODIES TO CANCER AND TO THE DETECTION OF CANCER |
| CA2752510C (en) | 2009-02-17 | 2024-01-23 | Neil Bander | Methods and kits for diagnosis of cancer and prediction of therapeutic value |
| EP3135302A1 (en) | 2009-12-02 | 2017-03-01 | Imaginab, Inc. | J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use |
| JP5859434B2 (ja) * | 2010-05-17 | 2016-02-10 | 株式会社カイオム・バイオサイエンス | ｉｎｖｉｖｏで抗腫瘍活性を有する抗ヒトＴＲＯＰ−２抗体 |
| WO2011155579A1 (ja) * | 2010-06-10 | 2011-12-15 | 北海道公立大学法人札幌医科大学 | 抗Ｔｒｏｐ－２抗体 |
| US8871908B2 (en) | 2011-11-11 | 2014-10-28 | Rinat Neuroscience Corp. | Antibodies specific for Trop-2 and their uses |
| US9427464B2 (en) | 2011-11-22 | 2016-08-30 | Chiome Bioscience Inc. | Anti-human TROP-2 antibody having an antitumor activity in vivo |
| MX2016010683A (es) | 2014-02-21 | 2017-05-11 | Ibc Pharmaceuticals Inc | Terapia para tratar enfermedades mediante la induccion de respuesta inmune de las células que expresan trop-2. |
| JP6746845B2 (ja) | 2015-04-22 | 2020-08-26 | イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． | 循環ｔｒｏｐ−２陽性癌細胞の単離、検出、診断及び／または特徴付け |
| SG10201913625XA (en) | 2015-08-07 | 2020-03-30 | Imaginab Inc | Antigen binding constructs to target molecules |
| US11266745B2 (en) | 2017-02-08 | 2022-03-08 | Imaginab, Inc. | Extension sequences for diabodies |
| CN113260384A (zh) | 2018-11-05 | 2021-08-13 | 西纳福克斯股份有限公司 | 用于靶向表达trop-2的肿瘤的抗体缀合物 |
| US20210316003A1 (en) | 2020-03-20 | 2021-10-14 | Immunomedics, Inc. | Biomarkers for sacituzumab govitecan therapy |
| WO2022078424A1 (zh) | 2020-10-14 | 2022-04-21 | 上海翰森生物医药科技有限公司 | 抗trop-2抗体、其抗原结合片段或其突变体、及其医药用途 |
| CN117295524A (zh) | 2021-06-02 | 2023-12-26 | 百奥泰生物制药股份有限公司 | 药物偶联物及其用途 |
| AU2022350725A1 (en) | 2021-09-23 | 2024-03-28 | Changzhou Hansoh Pharmaceutical Co., Ltd. | Antibody-drug conjugate, preparation method therefor, and pharmaceutical use thereof |
| AU2023241225A1 (en) | 2022-03-23 | 2024-08-29 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing trop-2 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5185254A (en) * | 1988-12-29 | 1993-02-09 | The Wistar Institute | Gene family of tumor-associated antigens |
| DE69027210T2 (de) * | 1989-04-21 | 1997-01-23 | Protein Design Labs, Inc., Palo Alto, Calif. | Rekombinantes antikörper-toxin-fusion-protein |
| CA2120507A1 (en) * | 1991-10-18 | 1993-04-29 | Alban J. Linnenbach | Soluble variants of type 1 membrane proteins, and methods of using them |
-
1996
- 1996-10-07 US US08/726,528 patent/US5840854A/en not_active Expired - Fee Related
- 1996-10-07 IL IL12329496A patent/IL123294A0/xx unknown
- 1996-10-07 CA CA002235269A patent/CA2235269C/en not_active Expired - Fee Related
- 1996-10-07 EP EP96936244A patent/EP0856054B1/en not_active Expired - Lifetime
- 1996-10-07 AU AU73942/96A patent/AU7394296A/en not_active Abandoned
- 1996-10-07 WO PCT/US1996/016070 patent/WO1997014796A1/en active IP Right Grant
- 1996-10-07 ES ES96936244T patent/ES2219699T3/es not_active Expired - Lifetime
- 1996-10-07 JP JP09515854A patent/JP2001501801A/ja not_active Ceased
- 1996-10-07 AT AT96936244T patent/ATE265532T1/de not_active IP Right Cessation
- 1996-10-07 DE DE69632333T patent/DE69632333T2/de not_active Expired - Fee Related
-
1998
- 1998-04-17 NO NO19981745A patent/NO321548B1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE69632333T2 (de) | 2004-12-30 |
| DE69632333D1 (de) | 2004-06-03 |
| AU7394296A (en) | 1997-05-07 |
| EP0856054A1 (en) | 1998-08-05 |
| NO981745D0 (no) | 1998-04-17 |
| NO321548B1 (no) | 2006-05-29 |
| CA2235269C (en) | 2006-09-19 |
| EP0856054B1 (en) | 2004-04-28 |
| US5840854A (en) | 1998-11-24 |
| JP2001501801A (ja) | 2001-02-13 |
| WO1997014796A1 (en) | 1997-04-24 |
| IL123294A0 (en) | 1998-09-24 |
| ES2219699T3 (es) | 2004-12-01 |
| MX9802129A (es) | 1998-05-31 |
| CA2235269A1 (en) | 1997-04-24 |
| ATE265532T1 (de) | 2004-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO981745L (no) | Monoklonalt antistoff BR110 og anvendelse av dette | |
| WO1997046589A3 (en) | Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods | |
| FI961285A (fi) | CD40:n vasta-aineita | |
| PT973550E (pt) | Anticorpos antagonistas anti-integrina avb3 | |
| ES2106195T3 (es) | Anticuerpo igg aglicosilado anti cd3. | |
| GB2383331A (en) | Monoclonal antibody DS6 Tumor-associated antigen CA6 and methods of use thereof | |
| DK0914155T3 (da) | Monoklonale antistoffer, der er spepcifikke for det ekstracellulære domæne af prostataspecifikt membran-antigen | |
| DE69939820D1 (de) | Internalisierende erbb2 antikörper | |
| ATE386116T1 (de) | Bindungsdomänen des serrate-proteins | |
| WO2004025248A3 (en) | Antibody pair screening methods | |
| IL162117A0 (en) | Humanized collagen antibodies and methods utilizing the same | |
| NL181461C (nl) | Werkwijze en reagenskit voor het bepalen van antigenen, antilichamen of antigeen-antilichaam-complexen of -conjugaten. | |
| WO2005046597A3 (en) | Antibodies to cd44 glycoforms and uses thereof | |
| ATE217086T1 (de) | Herstellung von photoprotein konjugaten und verfahren zu ihrer verwendung | |
| WO2003072727A3 (en) | EGFRvIII SPECIFIC MONOCLONAL ANTIBODY AND EGFRvIII RIBOZYMES AND USE TO DETECT, TREAT OR PREVENT EGFRvIII ASSOCIATED CANCER | |
| DE69717991D1 (de) | Ein monoklonaler antikörper, welcher ein apoptotisches antigen nachweist | |
| DK1121594T3 (da) | Fremgangsmåder til identifikation af hot-spot remanenser af bindende proteiner og små forbindelser som binder til samme | |
| DE59608073D1 (de) | Antikörper gegen ein, einen histidin-anteil aufweisendes fusionspolypeptid | |
| SE9902155L (sv) | Serum antibodies | |
| NO20001051D0 (no) | Monoklonale antistoffer som binder testosteron | |
| AU2169797A (en) | Improved production of antibodies through the use of antigen antibody complexes | |
| AU6068000A (en) | Peptide ligands that bind igm antibodies and block interaction with antigen | |
| BR1100555B1 (pt) | anticorpos monoclonais humanizados. | |
| ZA986064B (en) | Ancrod-specific monoclonal antibodies, antibody fragments, mixtures or derivatives thereof and their use. | |
| ATE50452T1 (de) | Mittel zum antigen/antikoerper-nachweis. |